BACKGROUND: Higher body mass index (BMI) was associated with slower human immunodeficiency virus (HIV) disease progression before the availability of effective antiretroviral therapy (ART), but the relationship between pretreatment BMI and CD4(+) lymphocyte recovery on ART is not well described. METHODS: We conducted an observational cohort study of HIV-infected, ART-naive adults starting treatment at a clinic affiliated with Vanderbilt University in Nashville, Tennessee. We assessed the relationship between pretreatment BMI and CD4(+) lymphocyte count change from baseline to 12 months in all subjects, among those with plasma HIV-1 RNA levels <400 copies/mL for ≥ 6 months and those with <10% change in weight during follow-up. Linear regression models were adjusted for age, sex, race, protease inhibitor usage, year of ART initiation, and baseline CD4(+) lymphocyte count and HIV-1 RNA level. RESULTS: A total of 915 patients met inclusion criteria; 78% were male, and their median age, BMI, and CD4(+) lymphocyte count were 39 years, 24 kg/m², and 171 cells/μL, respectively. The CD4(+) lymphocyte increase at 12 months was greatest among patients with a pretreatment BMI of ~25-30 kg/m² and diminished above and below this range (P = .03). Similar patterns were observed in the subgroup analyses. Among patients with a pretreatment CD4(+) lymphocyte count < 200 cells/μL, a BMI of ~25 kg/m² was associated with the highest odds of reaching a CD4(+) lymphocyte count > 350 cells/μL at 12 months (P = .05). CONCLUSIONS: 12-month immune reconstitution on ART was highest among patients commonly classified as overweight, suggesting there may be an optimal BMI range for immune recovery on ART.
BACKGROUND: Higher body mass index (BMI) was associated with slower human immunodeficiency virus (HIV) disease progression before the availability of effective antiretroviral therapy (ART), but the relationship between pretreatment BMI and CD4(+) lymphocyte recovery on ART is not well described. METHODS: We conducted an observational cohort study of HIV-infected, ART-naive adults starting treatment at a clinic affiliated with Vanderbilt University in Nashville, Tennessee. We assessed the relationship between pretreatment BMI and CD4(+) lymphocyte count change from baseline to 12 months in all subjects, among those with plasma HIV-1 RNA levels <400 copies/mL for ≥ 6 months and those with <10% change in weight during follow-up. Linear regression models were adjusted for age, sex, race, protease inhibitor usage, year of ART initiation, and baseline CD4(+) lymphocyte count and HIV-1 RNA level. RESULTS: A total of 915 patients met inclusion criteria; 78% were male, and their median age, BMI, and CD4(+) lymphocyte count were 39 years, 24 kg/m², and 171 cells/μL, respectively. The CD4(+) lymphocyte increase at 12 months was greatest among patients with a pretreatment BMI of ~25-30 kg/m² and diminished above and below this range (P = .03). Similar patterns were observed in the subgroup analyses. Among patients with a pretreatment CD4(+) lymphocyte count < 200 cells/μL, a BMI of ~25 kg/m² was associated with the highest odds of reaching a CD4(+) lymphocyte count > 350 cells/μL at 12 months (P = .05). CONCLUSIONS: 12-month immune reconstitution on ART was highest among patients commonly classified as overweight, suggesting there may be an optimal BMI range for immune recovery on ART.
Authors: Janice K Louie; Meileen Acosta; Michael C Samuel; Robert Schechter; Duc J Vugia; Kathleen Harriman; Bela T Matyas Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079
Authors: Nancy F Crum-Cianflone; Mollie Roediger; Lynn E Eberly; Kurt Vyas; Mike L Landrum; Anuradha Ganesan; Amy C Weintrob; Robert Vincent Barthel; Brian K Agan Journal: AIDS Date: 2010-04-24 Impact factor: 4.177
Authors: John R Koethe; Mohammed I Limbada; Mark J Giganti; Christopher K Nyirenda; Lloyd Mulenga; C William Wester; Benjamin H Chi; Jeffrey S Stringer Journal: AIDS Date: 2010-08-24 Impact factor: 4.177
Authors: R E Barth; J T M van der Meer; A I M Hoepelman; P A Schrooders; D A van de Vijver; S P M Geelen; H A Tempelman Journal: Eur J Clin Microbiol Infect Dis Date: 2008-07-16 Impact factor: 3.267
Authors: Vlada V Melekhin; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Gema Barkanic; Stephen P Raffanti; Timothy R Sterling Journal: PLoS One Date: 2009-09-09 Impact factor: 3.240
Authors: Barbara S Taylor; Yuanyuan Liang; L Sergio Garduño; Elizabeth A Walter; Margit B Gerardi; Gregory M Anstead; Delia Bullock; Barbara J Turner Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Barbara S Taylor; Kaku So-Armah; Janet P Tate; Vincent C Marconi; John R Koethe; Roger J Bedimo; Adeel A Butt; Cynthia L Gibert; Matthew B Goetz; Maria C Rodriguez-Barradas; Julie A Womack; Mariana Gerschenson; Vincent Lo Re; David Rimland; Michael T Yin; David Leaf; Russell P Tracy; Amy C Justice; Matthew S Freiberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-15 Impact factor: 3.731
Authors: James T Lee; Lauren A Saag; Aaron M Kipp; James Logan; Bryan E Shepherd; John R Koethe; Megan Turner; Sally Bebawy; Timothy R Sterling; Todd Hulgan Journal: AIDS Behav Date: 2020-04
Authors: Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice Journal: Clin Infect Dis Date: 2015-03-11 Impact factor: 9.079
Authors: M Nasi; S De Biasi; L Gibellini; E Bianchini; S Pecorini; V Bacca; G Guaraldi; C Mussini; M Pinti; A Cossarizza Journal: Clin Exp Immunol Date: 2016-08-09 Impact factor: 4.330
Authors: Sonia Napravnik; Joseph J Eron; Timothy R Sterling; Timothy Juday; Jonathan Uy; Richard D Moore Journal: AIDS Res Hum Retroviruses Date: 2012-11-12 Impact factor: 2.205